Wellcome Trust Clinical PhD Programme at the University of Oxford: a study of epigenetic changes in FOXP3 in regulatory T-cells and potential clinical application in allogeneic bone marrow transplantation. (360G-Wellcome-087333_Z_08_Z)
The proposed research will study the influence of demethylating agents on the development and expansion of regulatory T-cells (Tregs). Tregs provide a crucial cellular mechanism of peripheral tolerance and are important in controlling Graft-versus-Host disease (GvHD). Their development is dependent upon the expression of the transcription factor, FOXP3. However, in humans, transient FOXP3 expression can also be found in non-Treg cells, including activated conventional T-cells. It has been proposed that stable expression of FOXP3 in Tregs may be maintained by demethylation of the FOXP3 locus. We hypothesise that demethylating agents will increase FOXP3 demethylation, stable FQXP3 expression, Treg numbers and suppressive function and may modify GvHD following allogeneic BMT
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 234184 |
| Applicant Surname | Danby |
| Approval Committee | Neurosciences And Mental Health |
| Award Date | 2008-08-29T00:00:00+00:00 |
| Financial Year | 2007/08 |
| Grant Programme: Title | PhD Training Fellowship for Clinicians |
| Internal ID | 087333/Z/08/Z |
| Lead Applicant | Dr Robert Danby |
| Other Applicant(s) | Prof Herman Waldmann |
| Partnership Value | 234184 |
| Planned Dates: End Date | 2011-09-30T00:00:00+00:00 |
| Planned Dates: Start Date | 2008-10-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | South East |
| Sponsor(s) | Prof Rajesh Thakker |